

ADDENDUM: Apple Health Preferred Drug List (AHPDL) Class Names

The drug classes listed in the agenda have been shortened to allow for easier organization of the topics. The classes listed below reflect the exact naming used by the Washington State Health Care Authority for the AHPDL.

CYTOKINE AND CAM ANTAGONISTS
HEMATOPOIETIC AGENTS : ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
HEMATOPOIETIC AGENTS : GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)
HEMATOPOIETIC AGENTS : SICKLE CELL ANEMIA
IMMUNE MODULATORS : MYELOYDYSPLASTIC SYNDROMES
ONCOLOGY AGENTS : ALKYLATING AGENTS - ORAL
ONCOLOGY AGENTS : ANTIMETABOLITES - ORAL
ONCOLOGY AGENTS : ANTINEOPLASTICS MISC - ORAL
ONCOLOGY AGENTS : BCL-2 INHIBITORS - ORAL
ONCOLOGY AGENTS : HISTONE DEACETYLASE INHIBITORS - ORAL
ONCOLOGY AGENTS : IMMUNOMODULATORS - ORAL
ONCOLOGY AGENTS : ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS - ORAL
ONCOLOGY AGENTS : ISOCITRATE DEHYDROGENASE-2 (IDH2) INHIBITORS - ORAL
ONCOLOGY AGENTS : JANUS ASSOCIATED KINASE (JAK) INHIBITORS - ORAL
ONCOLOGY AGENTS : PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS - ORAL
ONCOLOGY AGENTS : PROTEASOME INHIBITORS - ORAL
ONCOLOGY AGENTS : XPO1 INHIBITORS - ORAL